Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 11—November 2025
Research Letter
Molecular Evidence of Dengue Virus Serotype 2 in Travelers Returning to Israel from the Sinai Peninsula
Neta S. Zuckerman1
, Guy Choshen1, Yaniv Lustig, Anna Shoykhet, Keren Friedman, Tatyana Kushnir, Ora Halutz, Hovav Azulay, Victoria Indenbaum1, and Eli Schwartz1
, Guy Choshen1, Yaniv Lustig, Anna Shoykhet, Keren Friedman, Tatyana Kushnir, Ora Halutz, Hovav Azulay, Victoria Indenbaum1, and Eli Schwartz1
Table
Epidemiology and test results of patients in study of molecular evidence of DENV-2 emergence from travelers returning to Israel from the Sinai Peninsula*
| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|---|---|---|---|
| Patient age, y/sex |
33/M |
40/F |
45/M |
19/M |
| DENV laboratory diagnostic analysis | ||||
| Sample collection date | 2024 Apr 22 | 2024 May 7 | 2024 Jun 5 | 2024 Jun 10 |
| Serum quantitative real-time PCR | DENV-2 (Ct 28) | DENV-2 (Ct 26.5) | DENV-2 (Ct 27) | DENV-2 (Ct 34) |
| Serum EIA IgM | Negative | Negative | Positive | Positive |
| Serum EIA IgG | Negative | Negative | Positive | Negative |
| DENV nonstructural protein 1 antigen | Positive | Positive | Negative | Positive |
*Ct, cycle threshold; DENV, dengue virus; DENV-2, DENV serotype 2; EIA, enzyme immunoassay.
1These authors contributed equally to this article.
Page created: September 18, 2025
Page updated: December 04, 2025
Page reviewed: December 04, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.